Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle East.

ABSTRACT:

Introduction

The presence of minimal residual disease (MRD) after curative-intent surgery for early-stage cancers is associated with disease recurrence. Circulating tumour deoxyribonucleic acid (ctDNA) has emerged as a promising biomarker for MRD assessment in patients with colorectal cancer (CRC) who have undergone surgery or completed adjuvant therapy. MRD tests are already available for use in clinics; however, treatment decisions following MRD results obtained in routine practice are infrequently described.

Methods

In this observational study, we report on the real-world clinical use of Guardant Reveal, a validated tissue-free MRD assay, in the first 215 consecutive patients (279 samples) with CRC tested in Asia and the Middle East.

Results

Overall, 22% of patient

SUBMITTER: Jain S 

PROVIDER: S-EPMC11449681 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature